As per our report, the Asia Pacific Contraceptives Market size was worth USD 5.74 billion in 2021 and estimated to reach USD 8.04 billion by the end of 2026, with a growing potential of 6.95%.
The need to avoid unplanned pregnancies and associated consequences are the key drivers driving the APAC contraceptives market. Therefore, the desire to avoid unintended pregnancies, particularly among young girls, is one of the major drivers of this market. It is more commonly referred to as fertility control or birth control, which is defined as preventing conception.
Moreover, the government initiatives and spreading awareness related to controlling the increasing population, its effects, and side effects can also be the reason for the market growth of contraceptives. In addition, non-contraceptive health advantages, including therapy for heavy menstrual bleeding, menstrual discomfort, and acne, are also cited by more than half of the women as reasons for usage; this can also drive the market's expansion.
The adverse side effects of the contraceptives, which include dizziness, irregular menstrual bleeding and causing of infertility, high cost of treatment, and availability of alternative contraceptives, can adversely affect the market growth of the contraceptives in this region.
Impact of COVID-19 on the APAC contraceptives market:
The COVID-19 epidemic has impacted negatively on healthcare services and technology around the world. It disrupted the demand and supply chain. Due to this pandemic, proper health care facilities and services were not available, as supply chains get disrupted, there were limited availability of contraceptives with product shortage and stockouts, lack of trained workers, and due to the lack of personal protective equipment to provide safe services, also due to the fear of COVID-19.
This research report on the APAC Contraceptives Market has been segmented & sub-segmented into the following categories:
By Drug Type:
By Medical Devices:
By End User:
Geographically, Asia Pacific profoundly influenced the industry in terms of demographics and lack of awareness within the large population. Favorable government initiatives about sex education are major factors expected to boost the contraceptives market growth over the forecast period.
The Indian Contraceptives Devices market is expected to grow at a CAGR of 7.42% during the forecast period. The need to decrease unwanted births and their repercussions is one of the main drivers driving the growth of the contraceptive business in India. One of the main causes of this demand is the desire to avoid unintended births, especially among young girls. However, non-contraceptive medical advantages, including medicine for extended menstrual bleeding, menstrual cramps, and acne, are also seen by less than half of women as motivations for usage.
The China Contraceptives Market is estimated to grow at a CAGR of about 7.98% during the forecast period. The factors such as rising instances of sexually transmitted illnesses and climbing in the government efforts to prevent these diseases can result in a growing need for preventative measures in such illnesses, which is likely to drive up demand for contraceptive devices. In addition, earlier China has also come up with the one-child policy to control its increasing population.
Also, countries such as Japan and Australia are estimated to grow healthy growth rates during the forecast period. The increased awareness of sexually transmitted diseases and the rising prevalence of unplanned pregnancies are the reasons that are propelling the industry forward and are responsible for the market growth.
KEY MARKET PLAYERS:
A few of the notable companies dominating the APAC contraceptives market are Bayer HealthCare AG, Teva Pharmaceutical Industries Limited, Medisafe Distribution Inc, Pace Pharmaceuticals Inc., Medicines360, Church & Dwight, Co., Inc., Actavis, Inc., CooperSurgical, Inc., Merck & Co., Inc., Reckitt Benckiser plc, Mayer Laboratories, Inc., and Pfizer, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug type
5.1.1 Contraceptive pills
5.1.2 Topical contraceptives
5.1.3 Contraceptive injectable
5.1.4 Others (contraceptive gels, jellies and creams)
5.2 By Medical Devices
5.2.1 Male contraceptive devices
5.2.2 Female contraceptive devices
188.8.131.52 Female condoms
184.108.40.206 Intrauterine devices
220.127.116.11 Contraceptive sponges
18.104.22.168 Contraceptive diaphragms
22.214.171.124 Contraceptive patches
126.96.36.199 Subdermal contraceptive implants
188.8.131.52 Non-surgical permanent contraceptive devices
6. Geographical Analysis
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bayer HealthCare AG
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Teva Pharmaceutical Industries Limited
8.3 Medisafe Distribution Inc
8.4 Pace Pharmaceuticals Inc
8.6 Church & Dwight, Co., Inc.
8.7 Actavis, Inc
8.9 Merck & Co., Inc
8.10 Reckitt Benckiser plc
8.11 Mayer Laboratories, Inc
8.12 Pfizer, Inc
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market outlook and Investment oppurtunities
a) List of Tables
b) List of Figures